Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review
We report the first case of severe asthma receiving dual biologics with tezepelumab and furthermore bronchial thermoplasty, and comprehensive literature review on dual biologics. Dual biologics may be an effective treatment method for severe asthma, requiring further investigation. (Source: Respirology Case Reports)
Source: Respirology Case Reports - December 7, 2023 Category: Respiratory Medicine Authors: Takeshi Matsumoto,
Yumiko Sakurai,
Noriyuki Tashima,
Tomoya Matoba,
Akiko Kaneko,
Takahiro Fujiki,
Yusuke Kusakabe,
Emi Nakayama,
Ayaka Tanaka,
Mayuko Tashima,
Naoki Yamamoto,
Kensaku Aihara Tags: CASE REPORT Source Type: research
Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research
A Randomized, Single ‐Dose, Parallel‐Controlled Phase I Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers
This study evaluated the bioequivalence of omalizumab, a humanized monoclonal antibody against immunoglobulin-E (IgE), with one of its biosimilar candidates. The study was designed as a randomized, double-blind, parallel-controlled trial. A total of subjects who met the inclusion criteria and did not meet the exclusion criteria were dynamically randomly assigned to receive the test drug or the reference drug with a single subcutaneous injection of 150 mg by the minimization method. The test group and the reference group had similar demographic characteristics and baseline characteristics of total IgE. The 90% confidence ...
Source: Clinical Pharmacology in Drug Development - December 6, 2023 Category: Drugs & Pharmacology Authors: Jie Cheng,
Chenguang Wang,
Jin Xu,
Chunyang Zhao,
Rong Song,
Yijun Wang,
Yang Zou,
Xunmin Zhang,
Yong Shan,
Jian Zhou,
Jing ‐Ying Jia Tags: Original Article Source Type: research
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein –protein interaction analyses
Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizuma... (Source: Respiratory Research)
Source: Respiratory Research - December 6, 2023 Category: Respiratory Medicine Authors: Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll and Scott T. Weiss Tags: Research Source Type: research
MECHANISMS OF HISTAMINE RELEASE FROM MAST CELLS BEYOND THE HIGH AFFINITY IgE RECEPTOR IN SEVERE CHRONIC SPONTANEOUS URTICARIA
Immunol Lett. 2023 Nov 30:S0165-2478(23)00195-5. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria (CSU) mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy (omalizumab). The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement syste...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients
CONCLUSION: A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.PMID:38042707 | DOI:10.1016/j.arbres.2023.11.011 (Source: Archivos de Bronconeumologia)
Source: Archivos de Bronconeumologia - December 2, 2023 Category: Respiratory Medicine Authors: Marcela Valverde-Monge Patricia S ánchez-Carrasco Diana Betancor Blanca Barroso Jos é Manuel Rodrigo-Muñoz Ignacio Mahillo-Fern ández Ebymar Arismendi Irina Bobolea Blanca C árdaba Mar ía Jesús Cruz Victoria Del Pozo Javier Dom ínguez-Ortega Franc Source Type: research
MECHANISMS OF HISTAMINE RELEASE FROM MAST CELLS BEYOND THE HIGH AFFINITY IgE RECEPTOR IN SEVERE CHRONIC SPONTANEOUS URTICARIA
Immunol Lett. 2023 Nov 30:S0165-2478(23)00195-5. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria (CSU) mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy (omalizumab). The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement syste...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients
CONCLUSION: A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.PMID:38042707 | DOI:10.1016/j.arbres.2023.11.011 (Source: Archivos de Bronconeumologia)
Source: Archivos de Bronconeumologia - December 2, 2023 Category: Respiratory Medicine Authors: Marcela Valverde-Monge Patricia S ánchez-Carrasco Diana Betancor Blanca Barroso Jos é Manuel Rodrigo-Muñoz Ignacio Mahillo-Fern ández Ebymar Arismendi Irina Bobolea Blanca C árdaba Mar ía Jesús Cruz Victoria Del Pozo Javier Dom ínguez-Ortega Franc Source Type: research
MECHANISMS OF HISTAMINE RELEASE FROM MAST CELLS BEYOND THE HIGH AFFINITY IgE RECEPTOR IN SEVERE CHRONIC SPONTANEOUS URTICARIA
Immunol Lett. 2023 Nov 30:S0165-2478(23)00195-5. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria (CSU) mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy (omalizumab). The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement syste...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
MECHANISMS OF HISTAMINE RELEASE FROM MAST CELLS BEYOND THE HIGH AFFINITY IgE RECEPTOR IN SEVERE CHRONIC SPONTANEOUS URTICARIA
Immunol Lett. 2023 Nov 30:S0165-2478(23)00195-5. doi: 10.1016/j.imlet.2023.11.008. Online ahead of print.ABSTRACTThere is growing evidence suggesting that in a subset of patients with severe chronic urticaria (CSU) mast cells are activated via mechanisms that bypass the high affinity IgE receptor. This might explain why some patients do not respond at all to anti-IgE therapy (omalizumab). The present article reviews the pathogenic mechanisms able to lead to histamine release from mast cells described so far in patients with CSU. These include the activation of the coagulation cascade, the activation of the complement syste...
Source: Immunology Letters - December 2, 2023 Category: Allergy & Immunology Authors: Riccardo Asero Source Type: research
